03.04.2018 13:30:00
|
Paradigm Spine Announces Company Activities And Three Podium Presentations Highlighting coflex® Interlaminar Stabilization® At ISASS 2018
NEW YORK, April 3, 2018 /PRNewswire/ -- Paradigm Spine, LLC, a leader in providing motion preservation solutions for the treatment of lumbar spinal stenosis, today announced its Company activities and scientific podium presentations on coflex® Interlaminar Stabilization® at the upcoming 2018 International Society for the Advancement of Spine Surgery (ISASS), being held April 11-13 in Toronto, Canada. coflex® is the only posterior lumbar motion preservation solution with proven long-term outcomes for durable pain relief and stability for patients with moderate to severe spinal stenosis.
"Now backed by two sets of Level I Evidence, coflex is the leading lumbar device shown to significantly maintain foraminal height, increase walking distance, and lower risk of secondary intervention, while still allowing patients a natural range of movement," said Marc Viscogliosi, Chairman and CEO of Paradigm Spine. "These proven long-term and durable results indicate that surgeons can be more confident when backing up their decompressions for spinal stenosis patients and when additional stabilization is required. We are pleased to be demonstrating the unique capabilities of coflex during three podium presentations, an industry symposium and an interactive workshop at this year's meeting."
Paradigm Spine Company Activities:
- Interactive Bioskills Experience: Demo Workshop for Posterior Lumbar Motion Preservation with coflex
Date and Time: Wednesday, April 11th, 6:00 – 8:30 p.m. EDT
Location: Hall G, Theater Red
This interactive demo workshop will be "come and go" style, and provide a closer look at coflex surgical pearls. Those interested in attending can RSVP on www.paradigmspineresources.com, email rsvp@paradigmspine.com or sign up at Paradigm booth #300. Walk-ins are also welcome. - Lunch Symposium: Extending the Durability of Decompression with the Exclusive Posterior Lumbar Motion Preservation Solution: Level I Evidence from Two Prospective Randomized Controlled Studies
Date and Time: Thursday, April 12th, 12:00 – 1:30 p.m. EDT
Location: Room 801B
Paradigm Spine will host a Lunch Symposium with a panel of speakers, featuring ESCADA author Dr. Joerg Franke and U.S. IDE Investigator Dr. Hyun Bae, discussing the results of the ESCADA 2-year trial results (European Study of coflex And Decompression Alone), for which researchers concluded decompression with coflex extends the durability and sustainability of a decompression procedure. Those interested in attending can RSVP on www.paradigmspineresources.com, email rsvp@paradigmspine.com or sign up at Paradigm booth #300 as space will be limited.
Paradigm Spine Podium Presentations:
- General Podium Presentation: Abstract 162 "5-year Follow-up of Interlaminar Stabilization Surgery in the ≤ 65 Year Old Patient: More Value, Less Cost"
Speaker: A.T. Brecevich
Date and Time: Wednesday, April 11th, 11:38 – 11:41 a.m. EDT
Location: Hall F - Lightning Podium Presentation: Abstract 527 "Medical Cost Savings for Lumbar Spinal Stenosis Treated with Decompression and Interlaminar Stabilization as an Alternative to Fusion"
Speaker: S.R. Golish
Date and Time: Wednesday, April 11th, 5:32 – 5:33 p.m. EDT
Location: Room 801B - Lightning Podium Presentation: Abstract 341 "Comparison of Decompression with Interlaminar Stabilization vs. Decompression with Fusion in Patients Requiring Surgical Treatment for Spinal Stenosis Grade I Spondylolisthesis at 5 Year Follow-Up"
Speaker: C. Dowe
Date and Time: Wednesday, April 11th, 5:47 – 5:48 p.m. EDT
Location: Room 802B
About Lumbar Spinal Stenosis (LSS)
Lumbar spinal stenosis (LSS), affecting 1.6 million patients annually in the United States, is a debilitating and degenerative disease often associated with significant leg and back pain, leg numbness and weakness, and significant reduction in an active lifestyle. Historically, the two traditional surgical treatment options for LSS included decompression alone or decompression with lumbar fusion. Decompression alone has proven effective at relieving pain symptoms caused by lumbar spinal stenosis, however, patients may not experience long term symptomatic relief, resulting in subsequent epidural injections for pain management, or additional surgeries for conversion to a fusion. Decompression with fusion has proven to provide pain relief and stabilize the diseased segment, but may lead to adjacent level disease requiring subsequent surgeries.
About Paradigm Spine, LLC:
Paradigm Spine, LLC, founded in 2004, is a privately held company and remains focused on the design and development of solutions for the disease management of spinal stenosis. The Company's signature product is the coflex® Interlaminar Stabilization® device, which is currently used in over 60 countries worldwide. coflex is the only lumbar spinal device that has produced Level I evidence in two separate prospective, randomized, controlled studies against two different control groups, changing the standard of care for lumbar spinal stenosis treatment. For additional information visit www.paradigmspine.com or www.coflexsolution.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/paradigm-spine-announces-company-activities-and-three-podium-presentations-highlighting-coflex-interlaminar-stabilization-at-isass-2018-300622999.html
SOURCE Paradigm Spine, LLC
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu MetLife Inc.mehr Nachrichten
21.11.24 |
S&P 500-Wert MetLife-Aktie: So viel Gewinn hätte ein Investment in MetLife von vor 3 Jahren eingefahren (finanzen.at) | |
14.11.24 |
S&P 500-Titel MetLife-Aktie: So viel Gewinn hätte ein Investment in MetLife von vor einem Jahr abgeworfen (finanzen.at) | |
07.11.24 |
S&P 500-Papier MetLife-Aktie: So viel Gewinn hätte eine MetLife-Investition von vor 10 Jahren eingebracht (finanzen.at) | |
31.10.24 |
S&P 500-Wert MetLife-Aktie: So viel Gewinn hätte eine MetLife-Investition von vor 5 Jahren eingebracht (finanzen.at) | |
29.10.24 |
Ausblick: MetLife mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
24.10.24 |
S&P 500-Titel MetLife-Aktie: So viel hätten Anleger mit einem Investment in MetLife von vor 3 Jahren verdient (finanzen.at) | |
17.10.24 |
S&P 500-Titel MetLife-Aktie: So viel hätten Anleger an einem MetLife-Investment von vor einem Jahr verdient (finanzen.at) | |
15.10.24 |
Erste Schätzungen: MetLife vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu MetLife Inc.mehr Analysen
Aktien in diesem Artikel
AutoNation Inc. | 164,70 | 6,29% | |
Brighthouse Financial Inc Registered Shs When Issued | 51,74 | 2,56% | |
FTI Consulting Inc. | 201,86 | 1,86% | |
MetLife Inc. | 82,89 | 6,53% | |
S&P Global Inc | 492,60 | 0,75% |